Skip to main content
Premium Trial:

Request an Annual Quote

RNAi Drug for Acute Hepatic Porphyria

The US Food and Drug Administration has approved the RNA interference drug givosiran (Alnylam Pharmaceuticals' Givlaari) to treat acute hepatic porphyria in adults, according to the agency.

Acute hepatic porphyria is an inherited disorder in which porphyrin accumulates during heme production and can lead to pain, paralysis, seizures and other symptoms, as MedPage Today reports. According to Alnylam, there are four types of acute hepatic porphyria, each of which stem from genetic alterations affecting enzymes in the liver's heme biosynthesis pathway. Givosiran is an RNAi drug that targets aminolevulinic acid synthase 1 mRNA to reduce its levels and the levels of toxins associated with attacks.

"Prior to today's approval, treatment options have only provided partial relief from the intense unremitting pain that characterizes these attacks," Richard Pazdur, the director of FDA's Oncology Center of Excellence and acting director of the Office of Oncologic Diseases says in a statement. "The drug approved today can treat this disease by helping to reduce the number of attacks that disrupt the lives of patients."

Reuters adds that the drug will cost about $575,000 per year.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more